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We describe a patient with idiopathic pleuroparenchymal ﬁbroelastosis (IPPFE). This rare clinicopatho-
logical syndrome is characterized by typical apical alterations op chest imaging, such as pleural thick-
ening and subpleural ﬁbrosis. Thickened visceral pleura and subpleural ﬁbrosis consisting of dense
collagen and elastin, are the main histopathological features. Etiology is unknown but a link between
recurrent infections (in particular aspergillosis) and autoimmune diseases is suspected. At this time there
is no standardized treatment regimen and the prognosis is variable.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
In this case report we describe a patient with idiopathic pleu-
roparenchymal ﬁbroelastosis (IPPFE). We will summarize the pa-
tient characteristics and give a brief overview of the cardinal
features of this disease.Case report
A 50-year-old female was referred to our university hospital
because of a puzzling case of interstitial lung disease. She pre-
sented with a progressive dyspnea on exertion and a non-
productive cough since 2 years. There were no other symptoms.
She had no relevant history and did not suffer from recurrent
respiratory infections. She never smoked nor was she exposed to
any potential noxious products or fumes. No major environmental
exposures, except a mold problem on a wall in her bedroom wereuppens).
Ltd. Open access under CC BY-NC-NDrevealed. She worked as a biology teacher and played the ﬂute.
There were no symptoms suggesting an underlying systemic
disorder.
Upon clinical examination we noted a patient in a good general
condition, without signs of chronic hypoxia such as clubbing or
cyanosis. Pulmonary auscultation only revealed some ﬁne crackles
on the basis of the left lung. Cardiac, abdominal and limb and joint
examination was normal. She had no suspect skin lesions. There
were no palpable adenopathies.
Pulmonary function testing showed a markedly reduced diffu-
sion capacity (TLco 3.90 mmol/min/Kpa or 45% of the predicted
value) and slightly reduced total lung capacity (TLC 4240 ml or 80%
of the predicted value).
Extensive biochemical analysis was normal with no signs of
(chronic) inﬂammation. There were no signs of any connective
tissue disease. Precipitins and speciﬁc IgE’s for aspergillus species
were negative. There was however an elevated stachybotrys atra
precipitin level, probably related to mold exposition in her
bedroom.
Bilateral patchy consolidations were noted on a conventional
chest radiograph. The alterations were mainly visible in the upper
lung zones. A high-resolution chest CT was performed, showing
marked bilateral pleural thickening as well as peribronchial cufﬁng
and some (traction) bronchiectasis. Moreover septal thickening
was mentioned, most pronounced in the subpleural region (Fig. 1). license.
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and basal regions were relatively spared.
Bronchoalveolar lavage showed a lymphocytic inﬂammation
(68% lymphocytes) with an increased CD4/CD8 ratio (4.0). Exten-
sive microbiological analysis and transbronchial biopsies were not
contributive to diagnosis.
This case was then presented on the interstitial lung diseases
multidisciplinary meeting. Based upon these ﬁndings, IPPFE was
suspected and a video-assisted thoracoscopic surgical (VATS) lung
biopsy was proposed to conﬁrm this diagnosis. VATS biopsies were
eventually obtained from the right middle and upper lobe. Micro-
scopic examination showed thickened ﬁbrotic pleura. Additional
Masson trichrome and elastin staining revealed marked subpleural
collagenous and elastinous deposition with an abrupt transition
between abnormal and normal lung parenchyma (Fig. 2). Diagnosis
of IPPFE was henceforth histopathologically conﬁrmed.
Our patient was treated with steroids that were gradually
tapered. Currently she still is being treated with methylpred-
nisolone 4 mg once daily. During this treatment the diffusion
capacity improved moderately (TLco 4.46 mmol/min/Kpa or 53%
of the predicted value after 6 months of treatment). Whether
exposition to stachybotrys contributed to disease development
remains unclear. Nevertheless sanitation of her room was
recommended.Fig. 1. Coronal (A) and axial (B, C) CT scan showing biapical ﬁbrotic pleural and subpleural
part of both lungs and normal lower lung zones.Discussion
IPPFE is a rare clinicopathological syndrome ﬁrst described in
2004 [1] with distinctive radiological and histopathological ﬁnd-
ings [2,3]. The recent published updated classiﬁcation of idiopathic
interstitial pneumonias (IIP) classiﬁes IPPFE in the group of rare
IIP [4].
Presenting symptoms are dyspnea on exertion, a dry cough and
recurrent respiratory tract infections. Spontaneous pneumothorax
and pneumomediastinum have been reported.
Imaging shows upper and middle lobe pleural thickening and
subpleural ﬁbrosis, in absence of lower lobe involvement. Honey-
combing, traction bronchiectasis and reticular abnormalities are
noted.
Histophathological ﬁndings are thickened visceral pleura and
subpleural ﬁbrosis consisting of dense collagen and elastin (hence
ﬁbroelastosis). Transition from pathological to normal parenchyma
is abrupt. Fibroblast foci and lymphocytic inﬂammation is variably
observed.
Etiology is unknown but recurrent infections (in particular by
aspergillus species), autoimmune diseases and genetic predispo-
sition seem to be linked. Several case reports of patients who
developed IPPFE after they underwent bone marrow trans-
plantation have been published [5]. Pleuroparenchymalchanges (arrows) together with peri-bronchovascular and linear opacities in the upper
Fig. 2. Pathology specimen obtained by video-assisted thoracoscopic surgery. Masson
trichrome stain shows a thickened visceral pleura (asterisk) and subpleural deposition
of collagen en elastin (white arrowheads) with an abrupt transition between normal
and abnormal parenchyma (black arrowheads). A:12.5 magniﬁcation and B:100
magniﬁcation.
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from restrictive allograft syndrome [6].
There is no consensus about treatment, although corticosteroids
are routinely used. Reddy et al [3] suggested that patients with
infection or autoimmunity require a speciﬁc approach. Patients
with a family history of IPPFE deserve a close follow-up due to a
more aggressive disease course. Due to the extreme rarity of this
syndrome, an experienced multidisciplinary team is essential in
(timely) identifying this disease as well as establishing an adequate
approach and follow-up. Therefore it is our belief that (early)
referral of IIP patients, especially when posing diagnostic difﬁ-
culties, to a center with an expert multidisciplinary panel is
indicated.
In summary, we present a patient with IPPFE, a rare clinico-
pathological syndrome. This case demonstrates the importance of
multidisciplinary approach in interstitial lung diseases.Acknowledgment
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